HWM
CRSP icon

HB Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

HB Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,101
Closed -$280K – 939
2024
Q1 		$280K Buy
4,101
+791
+24% +$56.6K ﹤0.01% 684
2023
Q4 		$207K Buy
+3,310
New +$183K ﹤0.01% 733
2022
Q4 		– Sell
-4,452
Closed -$291K – 695
2022
Q3 		$291K Sell
4,452
-100
-2% -$7.25K 0.01% 444
2022
Q2 		$277K Buy
4,552
+750
+20% +$44.1K 0.01% 458
2022
Q1 		$239K Hold
3,802
– – ﹤0.01% 512
2021
Q4 		$288K Buy
+3,802
New +$332K 0.01% 398

Other funds holding CRSP

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

HB Wealth Management's CRSP Position: Q2 2024 in Review

HB Wealth Management sold out of CRISPR Therapeutics (CRSP) in Q2 2024, closing a stake of 4,101 shares — an estimated $280K sold.

HB Wealth Management first reported a position in CRSP in Q4 2021 and held it in 6 quarters. The position peaked at $291K in Q3 2022. 449 funds tracked by Wall St. Rank hold CRSP as of Q2 2024.

  • HB Wealth Management reported no remaining CRISPR Therapeutics position as of Q2 2024 after selling out during the quarter.
  • HB Wealth Management sold 4,101 CRISPR Therapeutics shares in Q2 2024, an estimated $280K.
  • HB Wealth Management first reported a position in CRISPR Therapeutics in Q4 2021 and held it in 6 quarters.
  • HB Wealth Management's CRISPR Therapeutics position peaked at $291K in Q3 2022.
  • 449 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2024.

Based on HB Wealth Management's 13F filing for Q2 2024, filed 26 Jul 2024.